{
    "clinical_study": {
        "@rank": "114416", 
        "arm_group": {
            "arm_group_label": "Methotrexate", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is planned to evaluate the human factor (HF)/usability of pediatric or adolescent\n      JIA patients and the caregivers of Juvenile Idiopathic Arthritis (JIA) patients with the\n      Methotrexate Prefilled Pen (including a label comprehension assessment and a device\n      robustness evaluation)."
        }, 
        "brief_title": "Human Factors Study of Methotrexate Prefilled Pen (50 mg/mL) in Patients With Juvenile Idiopathic Arthritis", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Juvenile Idiopathic Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Juvenile Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Main Inclusion Criteria:\n\n          -  patient of either gender aged \u22652 to <21 years of age\n\n          -  is a suitable candidate for treatment with injectable methotrexate for JIA per the\n             patient's primary rheumatologist, with the previous or current diagnosis of active\n             polyarticular course JIA\n\n        Main Exclusion Criteria:\n\n          -  Is a female patient who is pregnant, trying to become pregnant, or breastfeeding, or\n             of childbearing potential, sexually active but not practicing a highly reliable\n             method of birth control during the study and at least 6 months thereafter\n\n          -  Has contraindications for methotrexate\n\n          -  Has a history of or current inflammatory arthritis or rheumatic autoimmune disease\n             other than JIA\n\n          -  Is unable, or does not have a caregiver able to comprehend written labeling and\n             training materials"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "20 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02052167", 
            "org_study_id": "MC-MTX.16/HF Children"
        }, 
        "intervention": {
            "arm_group_label": "Methotrexate", 
            "intervention_name": "methotrexate prefilled pen", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Methotrexate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kansas City", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "64108"
                }, 
                "name": "Children's Mercy Hospital & Clinics"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Human Factors Study for the Evaluation of the Methotrexate Prefilled Pen (50 mg/mL) for Subcutaneous Injection in Pediatric and Adolescent Patients With Juvenile Idiopathic Arthritis", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Test case scenarios were designed to determine if the potential risks associated with the use of the prefilled pen were mitigated by information contained in the patient leaflet and the training provided to each patient or caregiver. The test case scenarios with observation and performance measures will be evaluated.", 
            "measure": "Evaluation of test case scenarios with observation and performance measures", 
            "safety_issue": "No", 
            "time_frame": "8 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02052167"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "medac GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "medac GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}